Skystar Bio Pharmaceutical Company reported financial results for year ended December 31, 2011. For the year, the company reported revenues of $52.8 million, an 11% increase compared to the $47.6 million in revenues reported for the full fiscal 2010 year. Net income decreased 3% year over year to $13.7 million or $1.90 per basic and diluted share, as compared to $14.0 million or $1.97 per diluted share in the year ago period. Income from operations was $15,249,924 compared to $18,109,973 last year. Income before provision for income taxes was $16,528,939 compared to $17,389,042 last year. Net cash used in operating activities was $1,658,937 compared to net cash provided by operating activities of $7,719,676 last year. Purchases of plant and equipment were $524,574 compared to $4,126,954 last year. The company anticipates delivering top line revenue in the range of $53 million to $57 million with gross margins of roughly 50% for 2012. This is a conservative view that does not take into consideration the introduction of revenues from its new facilities to come online, although it does expects that there should be some partial revenue recognition to come from the new vaccine facility.